341 related articles for article (PubMed ID: 21344322)
21. Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas.
Cai J; Zhu P; Zhang C; Li Q; Wang Z; Li G; Wang G; Yang P; Li J; Han B; Jiang C; Sun Y; Jiang T
Oncotarget; 2016 Mar; 7(13):16384-95. PubMed ID: 26918938
[TBL] [Abstract][Full Text] [Related]
22. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas.
Nobusawa S; Watanabe T; Kleihues P; Ohgaki H
Clin Cancer Res; 2009 Oct; 15(19):6002-7. PubMed ID: 19755387
[TBL] [Abstract][Full Text] [Related]
23. Comparative study of IDH1 mutations in gliomas by high resolution melting analysis, immunohistochemistry and direct DNA sequencing.
Li J; Zhang H; Wang L; Yang C; Lai H; Zhang W; Chen X; Wang J
Mol Med Rep; 2015 Sep; 12(3):4376-4381. PubMed ID: 26130305
[TBL] [Abstract][Full Text] [Related]
24. Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1
Cai HQ; Wang PF; Zhang HP; Cheng ZJ; Li SW; He J; Zhang Y; Hao JJ; Wang MR; Yan CX; Wan JH
J Clin Pathol; 2018 Aug; 71(8):702-707. PubMed ID: 29550762
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical expression of IDH1 in gliomas: a tissue microarray-based approach.
Sipayya V; Sharma I; Sharma KC; Singh A
J Cancer Res Ther; 2012; 8(4):598-601. PubMed ID: 23361281
[TBL] [Abstract][Full Text] [Related]
26. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.
Agarwal S; Sharma MC; Jha P; Pathak P; Suri V; Sarkar C; Chosdol K; Suri A; Kale SS; Mahapatra AK; Jha P
Neuro Oncol; 2013 Jun; 15(6):718-26. PubMed ID: 23486690
[TBL] [Abstract][Full Text] [Related]
27. Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes.
Capper D; Sahm F; Hartmann C; Meyermann R; von Deimling A; Schittenhelm J
Am J Surg Pathol; 2010 Aug; 34(8):1199-204. PubMed ID: 20661018
[TBL] [Abstract][Full Text] [Related]
28. COLD PCR HRM: a highly sensitive detection method for IDH1 mutations.
Boisselier B; Marie Y; Labussière M; Ciccarino P; Desestret V; Wang X; Capelle L; Delattre JY; Sanson M
Hum Mutat; 2010 Dec; 31(12):1360-5. PubMed ID: 20886613
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors.
Takano S; Kato Y; Yamamoto T; Kaneko MK; Ishikawa E; Tsujimoto Y; Matsuda M; Nakai K; Yanagiya R; Morita S; Tsuboi K; Matsumura A
J Neurooncol; 2012 Jul; 108(3):361-73. PubMed ID: 22396072
[TBL] [Abstract][Full Text] [Related]
30. IDH1 mutation, a genetic alteration associated with adult gliomatosis cerebri.
Narasimhaiah D; Miquel C; Verhamme E; Desclée P; Cosnard G; Godfraind C
Neuropathology; 2012 Feb; 32(1):30-7. PubMed ID: 21481010
[TBL] [Abstract][Full Text] [Related]
31. A novel monoclonal antibody GMab-m1 specifically recognizes IDH1-R132G mutation.
Kato Y; Natsume A; Kaneko MK
Biochem Biophys Res Commun; 2013 Mar; 432(4):564-7. PubMed ID: 23485467
[TBL] [Abstract][Full Text] [Related]
32. Usefulness of immunohistochemical expression analysis of metabolic-related molecules in differentiating between intracranial neoplastic and non-neoplastic lesions.
Makino K; Nakamura H; Hide T; Yano S; Kuroda J; Takahashi Y; Iyama K; Kuratsu J
Brain Tumor Pathol; 2013 Jul; 30(3):144-50. PubMed ID: 23064941
[TBL] [Abstract][Full Text] [Related]
33. IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors.
Mellai M; Piazzi A; Caldera V; Monzeglio O; Cassoni P; Valente G; Schiffer D
J Neurooncol; 2011 Nov; 105(2):345-57. PubMed ID: 21643842
[TBL] [Abstract][Full Text] [Related]
34. Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes.
Seiz M; Tuettenberg J; Meyer J; Essig M; Schmieder K; Mawrin C; von Deimling A; Hartmann C
Acta Neuropathol; 2010 Aug; 120(2):261-7. PubMed ID: 20514489
[TBL] [Abstract][Full Text] [Related]
35. Detection of IDH1 mutation in the plasma of patients with glioma.
Boisselier B; Gállego Pérez-Larraya J; Rossetto M; Labussière M; Ciccarino P; Marie Y; Delattre JY; Sanson M
Neurology; 2012 Oct; 79(16):1693-8. PubMed ID: 23035067
[TBL] [Abstract][Full Text] [Related]
36. Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.
Kato Y
Brain Tumor Pathol; 2015 Jan; 32(1):3-11. PubMed ID: 25324168
[TBL] [Abstract][Full Text] [Related]
37. IDH1/2 gene hotspot mutations in central nervous system tumours: analysis of 922 Chinese patients.
Chen N; Yu T; Gong J; Nie L; Chen X; Zhang M; Xu M; Tan J; Su Z; Zhong J; Zhou Q
Pathology; 2016 Dec; 48(7):675-683. PubMed ID: 27780605
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic and prognostic value of alpha internexin expression in a series of 409 gliomas.
Ducray F; Mokhtari K; Crinière E; Idbaih A; Marie Y; Dehais C; Paris S; Carpentier C; Dieme MJ; Adam C; Hoang-Xuan K; Duyckaerts C; Delattre JY; Sanson M
Eur J Cancer; 2011 Mar; 47(5):802-8. PubMed ID: 21194923
[TBL] [Abstract][Full Text] [Related]
39. Diffuse gliomas in patients aged 55 years or over: A suggestion for IDH mutation testing.
Barresi V; Eccher A; Simbolo M; Cappellini R; Ricciardi GK; Calabria F; Cancedda M; Mazzarotto R; Bonetti B; Pinna G; Sala F; Ghimenton C; Scarpa A
Neuropathology; 2020 Feb; 40(1):68-74. PubMed ID: 31758617
[TBL] [Abstract][Full Text] [Related]
40. IDH1 mutation in pediatric gliomas: has it a diagnostic and prognostic value?
Buccoliero AM; Castiglione F; Degl'Innocenti DR; Gheri CF; Genitori L; Taddei GL
Fetal Pediatr Pathol; 2012 Oct; 31(5):278-82. PubMed ID: 22432788
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]